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EXPLANATORY  MEMORANDUM  AND  REPORT  TO  THE  COUNCIL 
I ,  Genera I  remarks 
( 1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
1.  When  the Council  adopted  Directive 87/22/EEcl,  and 
specifically Artlc!e 5  thereof,  It  Instructed  the Commission  to 
present  It  with  "proposals  for  Regulations  to harmonize,  along 
the  lines of  Directive 75/319/EEC,  the conditions  for 
authorizing  the manufacture  and  placing on  the market  of  the 
proprietary medicinal  products excluded  by  Article 34  of 
Directive 73/319/EEc2  and  of  the  veterinary medicinal 
products  referred to  In  Article 2(2)  of  Directive 
81/851/EECJ". 
2.  Three of  the  four  kinds of medicines  for  human  use which  were 
provisionally excluded  In  1975  have  recently been  Incorporated 
Into Community  pharmaceutical  legislation,  namely: 
OJ 
OJ 
OJ 
OJ 
OJ 
OJ 
OJ 
Immunological  medicinal  products  by  Directive 89/342/EEc4, 
radio-pharmaceuticals by  Directive 89/343/EEC5  and  medicinal 
products derived  from  human  blood  by  Directive 89/381/EEc6. 
In  the veterinary field,  a  proposal  for  a  Directive on 
Immunological  medicinal  products was  transmitted  to the Council 
In  January  19897.  It  has  proved more  difficult  to harmonize 
legislation on  homeopathic  medicinal  products  because of  the 
conflicting conceptions of medicine  Involved. 
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3.  While  homeopathic  medicine  has  traditionally been  recognized  In 
some  Member  States,  It  has merely  been  tolerated  In  others or  even 
Ignored  by orthodox  medicine  altogether.  Nonetheless,  homeopathy 
has  been  practised  In  Europe  for  more  than  two  centuries and  has 
become  Increasingly popular  with  the  public  In  the  last  decade  or 
so with  the  rise  In  "natural"  therapies and  alternative medicine. 
4.  It  Is  not  for  the  Commission  to  take sides  for  or  against  a 
particular style of medical  practice.  The  aim  should  be  rather,  in 
the  1  lght  of  legislative experience  In  some  of  the  Member  States, 
to provide European  consumers  with  safeguards about  the  Quality  and 
safety of  the  homeopathic  medicines  currently available  In  ali 
Community  countries.  Proof  of  therapeutic efficacy cannot  b~ 
obtained  by  generally accepted scientific methods  or,  at  the  !east, 
Is  highly  contentious. 
5.  Whether  recognized or  simply  tolerated,  homeopathic  remedies 
represent  a  small  but  not  Insignificant  share of  the 
pharmaceuticals market,  of  the order  of  half  a  bl II lon 
{500  000  000)  ECU.  Trade  between  Member  States  Is  Impeded  by  the 
differences  In  regulation and  practice at  national  level.  The 
proposals  the Commission  Is  now  presenting  to  the Council,  on 
homeopathic  medicinal  products  for  human  and  for  veterinary use, 
are  Intended  to  further  the  completion of  the  Internal  market  In 
the pharmaceuticals sector as  provided  for  In  the  1985  White  Paper 
programme. - 4  -
II.  ALTERNATiVE  REMEDIES  IN  EUROPE 
6,  In  1987  the Commission  asked  the Belgian Consumers'  Association  to 
carry out  a  study on  the market  for  alternative medicine  among 
European  consumers.  This study,  written by  G.  Sermus,  covers seven 
Community  countries  {B~Iglum,  Denmark,  Germany,  France,  Italy, 
Netherlands,  United  Kingdom)  as well  as  Finland and  Switzerland.  It 
shows  that  a  considerable proportion of  the population  (from  18%  to 
75%  depending  on  country)  makes  use of  alternative therapies. 
Homeopathy  Is  the  principal  method  among  them,  well  ahead  of 
acupuncture  and  manipulations such  as chiropractic,  osteopathy and 
various  types of massage.  Then  come  herbal  remedies,  followed  by 
what  one  might  ca II  "paranorma I"  methods,  IncludIng  myst I  ca I  and 
religious approaches.  Finally  the author  lists what  he  classifies 
as  fringe methods  (In  Europe)  such  as  lrldology,  anthroposophy, 
"biomedicine",  aroma  therapy,  cell  therapy and  hypnotherapy.  The 
author  notes  that  It  Is  generally adults  between  the ages of  40  and 
60  with  a  high  level  of education who  make  most  use of alternative 
medicine. 
7.  These  diverse  therapies have  little  In  common  except  being almost 
uniformly  rejected by  science as  lacking  a  rational  basis.  Whereas 
conventional  or  allopathic medicine  has  made  considerable  progress 
through  advances  In  biology,  pharmacology  and  surgical  techniques, 
the various  forms  of  alternative medicine  generally adopt  an 
empirical  approach  backed  by  what  are often obscure explanations. 
But  conventional  medicine  Itself does  not  meet  alI  the expectations 
of patients with certain chronic or  supposedly  "Incurable" 
diseases.  Furthermore,  patients are often put  off  by  the  Impersonal 
and  highly  technological  nature of  modern  medicine.  The  alternative 
medicines,  on  the other  hand,  tend  to be  holistic  In  the sense  that 
they  look  at  the  person as a  whole  and  encourage  the patient  to 
participate  In  the  healing process.  Although  alternative medicine 
can  be  sincere  In  approach  and  rest on  established traditions,  It 
must  be  admitted  that  a  degree of opportunism  has  developed  to 
exploit  recent  fashions,  even  to  the extent of  combining  methods 
that  are  Incompatible. - 5  -
8.  Homeopathic  remedies  represent  by  far  the most  Important  type of 
alternative medicines  used  In  Europe.  For  our  present  purposes, 
plant-based medicinal  products wll I  be  considered as  belonging  to 
the allopathic or  conventional  tradition;  medicinal  herbs are  In 
fact  the origin of  many  modern  medicines,  either  by  extraction or 
by  synthesis,  although  the action of  the  plant  as a  whole  may  be 
poorly  understood.  While  allopath:/  treats a  condition by  tackling 
the causes or,  at  second-best,  the symptoms,  homeopathy  Is  based on 
the principle of similarity- like cures  like- and  extreme 
dilutions.  The  theory was  developed  by  Samuel  Hahnemann  (1755-1843) 
and  consists of  trying to cure  the patient  by  administering very 
small  doses of  a  substance which,  In  a  healthy  Individual,  would 
produce similar  symptoms  to  those observed  In  the patient.  This 
theory  has  evolved  Into various opposing  schools:  complexlsts, 
pluralists ("materialists")  and  unlclsts  ("dynamists"). 
Anthroposophy  (following Rudolf  Steiner)  and  "biomedicine" 
(following  Dr  Schussler),  which  are more  widespread  In  Germany  than 
In  the rest of  the Community,  make  frequent  use of  homeopathic 
remedies  while  being  based on  other  Ideas. 
9.  When  the Community's  pharmaceuticals directives were  being 
transposed  Into German  law  In  the  "Arznelmlttelgesetz  1976",  a 
wide-ranging debate  took  place about  the position of  alternative 
remedies.  The  quality of  homeopathic  and  anthroposophlc medicines 
Is standardized  In  a  separate official  pharmacopoeia 
(Hom5opathlsches  Arznelbuch- HAB);  such  medicinal  products are 
evaluated by  special  committees of  the  Federal  Health Office 
(Bundesgesundheltsamt- BGA).  France  also has  a  well-established 
homeopathic  tradition,  with  special  authorization procedures  and 
the  Inclusion of monographs  on  homeopathic  preparations  and  'mother 
tinctures'  or  stocks  In  the  French  I~  editions  VI  I I  and 
X1.  Homeopathic  m~dlcinal  products are also mant  oneo,  albeit  in 
much  less detail,  In  the  pharmaceutical  legls:e<  on of  Belgium, 
Drinmark,  the  Netherlands,  the  United  Kingdom  ana  Ire!  .  Th~~e 
c<,tmtrles,  as wei  as  Italy  and  Portugal,  ar~  w~lting to  see  what 
acnon  the  Community  will  talce  bef;;;,r'=  review  ng  their  own 
lf,g  s I at I on. - 6  -
Ill.  CONSULTATIONS  AT  COMMUNITY  LEVEL 
10.  In  the  period since 1987,  the  Commission  has  put  three 
successive preliminary drafts of  a  Directive on  homeopathic 
medicinal  products  to  the  Pharmaceuticals Committee,  which  Is 
composed  of  representatives of  the Uember  States.  The  reaction 
to these drafts varied widely  according  to the different 
national  positions,  from  official  recognition  to outright 
rejection.  Since  homeopathic  medicines are available on  all  the 
national  markets,  there have  been  suggestions  that  they  be 
classified as articles for  household  consumption  rather  than  as 
medicines.  However,  this does  not  seem  consistent either with 
the Community  definition of medicinal  products or  with  the 
Instructions given  by  the Council.  While  some  convergence of 
views  seems  possible  In  the case of  traditional  homeopathic 
medicines,  the  same  cannot  be  said of  anthroposophlcal 
products,  nor  of  aspects felt  to carry  too much  risk 
(preparations for  Injection,  for  example)  or  considered hardly 
compatible with  the  basic principles of  homoeopathy 
(encouragement  of  self-medication). 
11.  The  preliminary draft  Directive on  homeopathic  medicinal 
products  for  human  use  was  distributed widely  through  several 
European  organizations  representing professionals  In  the  field: 
the  pharmaceuticals  Industry  (EFPIA),  homeopathic  and 
anthroposophlc  laboratories,  the Association of  EEC  pharmacists 
and  mutual  pharmacies,  and  homoeopaths  and  anthroposophlcal 
practitioners.  The  overall  reaction was  positive,  since  the 
draft  text  Introduced greater  legal  security while eliminating 
various sharp practices which  damage  the  reputation of serious 
practitioners.  At  the  request  of  the  Commission,  the Consumers' 
Consultative Committee  Issued  an  opinion on  16  February  1989; 
this was  favourable,  and  was  accompanied  by  complete  and 
detailed  reference documentation.  In  addition  to this,  an 
International  workshop  en  homeopathic  medicines was  held  In 
Berlin on  2  and  3  February  1989  at  the  Invitation of  the 
Federal  Health Office;  11  health ministries of  European 
countries were  represented,  as  we!!  as  the Commission.  Most  of 
the  ji)artlclpants met  again  In  Strasbourg on  17  and  18  May  at 
the  Invitation of  the  Secretary of  the  European  rnarmaoopsela. - 7  -
12.  Several  prel lmlnary  drafts of  a  Directive on  medicinal  products  for 
veterinary use  have  been  submitted  to  the  Committee  for  Veterinary 
Medicinal  Products.  Despite  the great  differences  between 
countries,  most  members  of  the  Committee  underlined  the  need  to 
Improve  standards of  quality and  safety  for  this category of 
medicines,  which  are  being  used more  and  more.  The  competant 
authorities would  also  like  to el lmlnate  a  number  of  abuses  In  the 
field,  In  particular  the sale of medicines  described as  homeopathic 
for  collectively treating  livestock as part of  specific medications 
for  which  a  therapeutic effect  has  not  been  shown. 
IV.  THE  QUALITY  OF  HOMEOPATHIC  MEDICINES 
13.  Homeopathic  medicinal  products are  defined  primarily  by  the  way 
they  are made  up,  as described  In  the  European  Pharmacopoeia  If  It 
Is extended  to  Include  homeopathy  or,  If  not,  In  national 
pharmacopoeias  (currently  those of  France  and  Germany).  This 
"objective" method  of definition,  which  Is  the one  adopted  In  the 
German  legislation,  has  the  advantage  of  not  taking sides  In  the 
argument  over  the  philosophy or  rational  basis of  homeopathy  or 
other  traditions using  the  same  products,  such  as  Is often  the  case 
for  anthroposophy.  Homeopathic  medicines  should be  clearly 
Identifiable as  such  for  the  general  public,  by  means  of  a  special 
legend  on  the  label,  so  that  there can  be  no  confusion  between 
these,  more  controversial,  homeopathic  products  and  orthodox 
medicines.  The  general  approach  of  Community  pharmaceutical 
legislation  Is  followed  In  that  the proposals cover  only medicines 
which  are widely distributed,  I.e.  prepared  Industrially and  thus  a 
major  potential  risk  for  the public,  In  particular  by  being sold  In 
Intra-Community  trade.  This would  not  affect  In  any  way  the  right 
to prescribe or  prepare other  alternative  therapies  In  Individual 
cases according  to magistral  or officinal  formulae,  within  the 
bounds  of  current  national  legislation. - 8  -
14.  The  wide  distribution of  Industrially prepared  homeopathic 
medicines means  that  the first  priority must  be  to harmonize  the 
manufacture  and  monitoring of  them.  Apart  from  having  to comply 
with  the  European  Pharmacopoeia or,  If  not  covered  by  It,  the 
existing official  pharmacopoeias,  homeopathic  medicines will  become 
subject  to all  the Community  rules safeguarding  the quality of 
medicinal  products manufactured  In  and  Imported/exported  to or  from 
the Community.  A consequence  Is  that  the  authorization  to 
manufacture,  export  or  Import  such  products wll I  be  conditional  on 
possession of  suitable premises and  equipment.  All  raw  materials 
and  each  batch manufactured will  have  to be  monitored  by  a 
qualified person,  who  will  Issue  a  properly  registered certificate 
of  conformity.  The  rules of  good  manufacturing  practice  (GMP)  wl  II 
become  mandatory,  which  Is  particularly  Important  In  the  case of 
highly dl luted  products.  Establishments wll I  also become  subject  to 
regular  monitoring  by  pharmaceuticals  Inspectors.  The  competent 
authorities  In  the Member  States will  be  required  to exchange 
Inspection  reports and  other  data  relevant  to safeguarding  the 
quality and  safety of  homeopathic  medicines. 
V.  PLACEMENT  OF  HOMEOPATHIC  MEDICINES  ON  THE  MARKET 
15.  Harmonizing  the  terms  on  which  homeopathic  medicines  are  to  receive 
market  authorization poses more  complicated problems.  Some  Member 
States,  while  accepting  that  it  Is  useful  to ensure  the quality of 
homeopathic  products,  do  not  want  to give  them  official  status and 
yet  are prepared  to admit  products  legally sold  In  other  Member 
states, within certain constraints.  On  the other  hand,  where  a 
Member  state wishes  to regulate  the marketing of  homeopathic 
medicines  It  wl  II  have  a  choice between  two  different  regimes. - 9  -
16.  Tha  first of  these,  full  harmonization,  consists of  a  slmpl !fled 
registration procedure applicable  to medicinal  products which, 
without  therapeutic claims  being made,  are  put  up  In  pharmaceutical 
forms  and  at  dilutions that  carry  no  risk.  Such  medicines,  sold 
under  their  common  name  and  bearing  a  fully  harmonized  label I ing, 
wl  11  usually  be  prescribed by  a  practitioner  qualified according  to 
the specific features of  the case  under  treatment.  Medicines of 
this  type will  be  considered  to belong  to  the  homeopathic  tradition 
and  their  therapeutic effect  Is  to be  assessed  In  terms  of  that 
tradition.  Since  some  of  the  Information would  be  repetitive,  It 
wl  II  be  possible  to combine  dossiers  to cover  a  series of  like 
preparations. 
17.  The  other,  and  more  rigorous,  regime  cannot  be  entirely harmonized 
at  this  juncture.  For  homeopathic  medicines other  than  those 
qualifying  for  the simplified registration procedure,  proof of 
therapeutic effect  balanced against  potential  risks wl  II  have  to be 
provided.  Member  States will  apply either  the ordinary  rules on 
market  authorization,  especially criteria of efficacy  and  safety, 
or  special  rules  for  homeopathic  preparations.  In  this second  case, 
these special  rules will  have  to be  notified  to  the  Commission  with 
a  view  to  later  harmonization. 
VI.  CONCLUSIONS 
18.  By  1993,  with  the entry  Into effect of  the Directives,  homeopathic 
medicines  sold  In  the Community  will  all  have  to meet  the  same  high 
quality standards.  First-time appl lcatlons  for  registration or 
authorization will  be  examined  under  the  terms  of  the Directives. 
Experience with  Implementation  wll I  lead  to a  greater  convergence 
of  practice as  between  Member  States despite  the present  wide 
differences. - 10  -
In  accordance  with Articles Sa  and  8c  of  the Treaty establishing 
the  European  Economic  Community,  the  Commission  calls on  the Member 
States to  take  the necessary steps to comply  with  the  proposals 
presented here  by  1  January  1993. 
19.  The  Commission  has  given  due  consideration  to  the  requirements of 
Article 8c  of  the  Treaty and  has  concluded  that  no  special 
provisions are needed  In  this case. 
The  commission  has  also  looked  at  the matter  of  the  high  level  of 
protection  for  health,  safety,  the  environment  and  consumers 
required  by  the  third paragraph of Article  100a.  This  review was 
conducted after consulting concerned  parties and  after  analysing 
the  Inherent  risks  In  this area,  given current  technical  capacity 
within  European  Industry.  The  proposals  take  full  account  of  these 
factors,  In  the  light of  the underlying  alms  of  the Treaty. ~-~---~--~----~------------------
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THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to the Treaty establishing  the  European 
Economic  Community,  and  in  particular  Article  100a 
thereof, 
Having  regard  to  the  proposal  from  the  Commission, 
In  cooperation with  the European Parliament, 
Having  regard  to  the  opinion  of  the  Economic  and 
Social  Committee, 
Whereas  differences  currently  ex1stmg  between  the 
provisions laid down by law, regulation or administrative 
action in the Member States may hinder trade in homeo-
pathic medicinal products within the  Community; 
Whereas  the  essential  aim  of any  rules  governing  the 
production,  distribution  and  use  of medicinal  products 
must  be  to safeguard public health; 
Whereas  the  proVISIOns  of  Council  Directive 
65/65/EEC (')  and  the  Second  Directive 
75/319/EEC ('),  as  last  amended  by  Directive 
891341/EEC ('), are not always  appropriate for homeo-
pathic medicinal  products; 
Whereas  homeopathic  medicine  is  officially  recognized 
in  certain  Member States  but is  only  tolerated  in  other 
Member  States;  whereas,  therefore,  it  is  appropriate  to 
recognize  certain  national  homeopathic  traditions 
without imposing them throughout the  Community; 
(')  OJ No 22,  9.  2.  1965, p.  369/65. 
(')  OJ No L  147,  9.  6.  1975, p.  13. 
(')OJ No L  142,  25.  5.  1989,  p.  11. 
Whereas  even  if homeopathic  remedies  are  not  always 
officially  recognized,  they  are  nevertheless  prescribed 
and  used in  all  Member States; 
Whereas  it  is  desirable  in  the  first  instance  to  provide 
users  of these  remedies  with  a  clear indication  of their 
homeopathic character and with sufficient guarantees of 
their quality and safety; 
Whereas  the  rules  relating  to  the  manufacture,  the 
control  and  inspection  of  homeopathic  medicinal 
products  must  be  harmonized  to permit  the  circulation 
· throughout  the  Community  of preparations  which  are 
safe and of good quality; 
Whereas,  having  regard  to the  particular characteristics 
of  these  medicinal  products,  such  as  their  very  low 
content of active principle.s  and the difficulty of applying 
to them  the conventional  statistical  methods  relating  to 
clinical  trials,  it  is  appropriate  to  provide  a  simplified 
registration  system  for  those  traditional  homeopathic 
medicinal  products  which  are  placed  on  the  market 
without specific  therapeutic indications  in  a preparation 
which  does not present a risk for the  patient; 
Whereas,  however,  the  usual  rules  governing  the  auth-
orization to market medicinal products should be  applied 
to  a  homeopathic  medicinal  product  marketed  with 
therapeutic indications  or in  a  form  which  may present 
risks  which must  be  balanced  against the  desired  thera-
peutic effect; whereas those Member States which have a 
homeopathic tradition should be  able  to apply particular 
rules  for  the  evaluation  of tests  and  trials  intended  to 
establish  the  safety  and  efficacy  of  these  medicinal 
products  provided  that  they  notify  them  to  the 
Commission, 1.  5.  90  Official Journal of the European Communities  No C 108/11 
HAS  ADOPTED THIS DIRECTIVE: 
CHAPTER I 
Scope 
Article 1 
For  the  purposes  of  this  Directive  'homeopathic 
medicinal  product'  shall  mean  any  medicinal  product 
prepared  in  accordance  with  a  homeopathic  manufac-
turing  procedure  described  by  the  European  Pharma-
copoeia  or,  in  the  absence  thereof,  by  the  official 
pharmacopoeia of a  Member State. 
Homeopathic preparations are produced from  products, 
substances or compositions called homeopathic stocks by 
successive  dilutions. 
Article 2 
1.  The  proviSIOns  of  this  Directive  shall  apply  to 
industrially prepared homeopathic medicinal products for 
human  use  to  the  exclusion  of homeopathic  medicinal 
products prepared in  accordance with a magistral or an 
officinal  formula  as  defined  in  Article  1  of  Directive 
65/65/EEC. 
2.  The medicinal products referred to in  paragraph  1 
must  be  identified  by  the  inclusion  on  their  labels  in 
clearly legible form of the words 'homeopathic medicinal 
product'. 
CHAPTER II 
Manufacture,  control and  inspection 
Article 3 
The provisions of Chapter IV of Directive 75/319/EEC 
shall  apply  to  the  manufacture,  control,  import  and 
export of homeopathic medicinal products. 
Article 4 
The measures of supervision and the sanctions provided 
for in Chapter V of Directive 75/319/EEC shall apply to 
homeopathic  medicinal  products  together with  Articles 
31  and  32  of the same  Directive. 
However,  the  proof of therapeutic effect mentioned in 
Article  28  (1)  (b)  of the  same  Directive  shall  not  be 
required  for homeopathic medicinal products registered 
in  accordance with Article  7 of this  Directive. 
Article 5 
The Member States shall communicate to each other all 
the  information  necessary  to guarantee  the  quality and 
safety of homeopathic medicinal products manufactured 
and  marketed within  the  Community,  and in  particular 
the  information  mentioned  in  Articles  30  and  33  of 
Directive 75/319/EEC. 
CHAPTER III 
Placing  on the market 
Article 6 
1.  Member  States  shall  ensure  that  homeopathic 
medicinal  products  manufactured  and  marketed  within 
the  Community  are  registered  or  authorized  in 
accordance with  the  provisions  of Articles  7,  8  and  9. 
Each  Member State shall  take registrations  and author-
izations  previously  granted  by  another  Member  State 
into due consideration. 
2.  A Member State may refrain from  establishing any 
system of registration or authorization for homeopathic 
medicinal  products.  A  Member  State  applying  this 
provision  shall  inform  the  Commission  thereof.  The 
Member  State  concerned  shall  allow  the  use  in  its 
territory  of homeopathic  medicinal  products  registered 
or  authorized  by  other  Member  States  in  accordance 
with Articles  7,  8 and 9. 
Article  7 
1.  Homeopathic medicinal products shall be subject to 
a  simplified  registration  procedure  if  they satisfy all  of 
the following  conditions: 
they are administered orally or externally, 
- they  are  marketed  without  any  specific  therapeutic· 
indication, whether on the labelling of the product or 
in any accompanying product information, 
- there  is  a  sufficient  degree  of dilution  to guarantee 
the safety of the preparation; in particular, the  prep~ 
aration shall contain less than one part per million of 
any  active  principle  which  is  subject  to  the 
requirement of a medical prescription. 
2.  In  addition  to  the  clear  mention  of  the  words 
'homeopathic  medicinal  product',  the  labelling  and 
packaging  of  the  homeopathic  medicinal  products 
referred to in  paragraph 1 shall consist of the following 
information and no other information: 
the  scientific  name  of  the  stock  followed  by  the 
degree  of  dilution,  using  the  symbols  used  10  the 
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- name  and  address  of  the  person  responsible  for 
marketing, and of the manufacturer, 
method of administration, 
- expiry date, in plain language, 
- special storage precautions, if any, 
- manufacturer's batch number, 
- registration number. 
3.  The criteria and rules of procedure provided for in 
Articles  5 to  12  of Directive 65/65/EEC shall  apply to 
the  simplified  registration  procedure  for  homeopathic 
medicinal  products, with  the  exception  of the proof of 
therapeutic effect. 
Article 8 
An application for a simplified registration submitted by 
the person responsible  for marketing may cover a series 
of  preparations  derived  from  the  same  homeopathic 
stock.  The following  documents  shall  be  included  with 
the application in order to demonstrate, in particular, the · 
pharmaceutical  quality  and  the  batch"to-batch 
consistency of the products concerned: 
- scientific  name  of the  homeopathic  stock,  together 
with  a  mention  of  the  various  routes  of  adminis-
tration,  pharmaceutical  forms  and  dilutions  to  be 
registered, 
- dossier  describing  how  the  stock  is  obtained  and 
controlled, and justifying its  homeopathic nature, on 
the basis of an adequate homeopathic bibliography, 
manufacturing  and  control  file  for  each  pharma-
ceutical  form  and  a  description  of  the  method  of 
dilution, 
- manufacturing  authorization  for  the  preparations 
concerned, 
copies of any registrations or authorizations obtained 
for the same preparations in other Member States, 
one  or  more  specimens  or  mock-ups  of  the  sales 
presentation of the preparations to be registered. 
Article  9 
1.  Homeopathic medicinal  products  other than those 
referred to in  Article  7  shall  be  authorized and labelled 
in  accordance with the provisions of Articles  5 to 21  of 
Directive  65/65/EEC  and Articles  1  to  7  of Directive 
75/319/EEC, including the provisions  concerning proof 
of therapeutic effect. 
2.  A  Member State  may  lay  down  specific  rules  for 
the pharmacological  and toxicological  tests  and  clinical 
trials  of  homeopathic  medicinal  products  other  than 
those  referred  to  in  Article  7.  In  this  case,  before  the 
date  referred  to  in  Article  10  (1)  the  Member  State 
concerned  shall  notify  the  Commission  of the  specific 
rules  in  force. 
CHAPTER IV 
Final provisions 
Article 10 
1.  Member States shall take the measures necessary to 
comply with this  Directive by  31  December 1992.  They 
shall inform the Commission thereof forthwith. 
The  provlSlons  adopted  pursuant  to  the  first 
subparagraph  shall  make  express  reference  to  this 
Directive. 
2.  Applications for registration or for marketing auth-
orization for products covered by this  Directive  lodged 
after the  date set out in paragraph  1 shall  comply with 
the provisions of this  Directive. 
Article  11 
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Proposal' for a Council Directive widening the scope of Directive 81/851/EEC on the approxi-
mation  of the  laws  of the  Member  St~tes on veterinary  medicinal  products  and  laying  down 
additional  provisions  on homeopathic veterinary medicinal products 
[COM(90)  72 final- SYN 252} 
(Submitted by  the  Commission  on  23 March  1990) 
(90/C 108/06) 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having regard to the  Treaty establishing  the  European 
Economic  Community,  and  in  particular  Article  100a 
thereof, 
Having  regard  to  the  proposal  from  the  Commission, 
In  cooperation with  the European Parliament, 
Having  regard  to  the  opmwn  of  the  Economic  and 
Social Committee, 
Whereas differences between the provisions laid down by 
law,  regulation  or administrative  action  in  the  Member 
States  may  hinder  trade  in  homeopathic  veterinary 
medicinal products within the Community; 
Whereas  the  essential  aim  of any  rules  governing  the 
production, distribution  and use  of veterinary medicinal 
products must be to safeguard human and animal health; 
Whereas  the  prov!Slons  of  Council  Directive 
81/851/EEC (I)  are  not always  appropriate for homeo-
pathic veterinary medicinal products; 
Whereas  homeopathic  medicine  is  officially  recognized 
in  certain  Member States  but is  only tolerated  in  other 
Member States;  whereas,  therefore,  it  is  appropriate  to 
recognize  certain  national  homeopathic  traditions 
without imposing them throughout the  Community; 
Whereas  even  if  homeopathic  remed;es  are  not  always 
officially  recognized,  they  are  nevertheless  prescribed 
and used in  all  Member States; 
Whereas  it  is  desirable  in  the  first  instance  to  provide 
users  of these  remedies  with  a  clear indication  of their 
C)  OJ No L 317,  6.  11.  1981, p.  1. 
homeopathic character and with sufficient guarantees of 
their quality and safety;  · 
Whereas  the  rules  relating  to  the  manufacture,  the 
control  and  inspection  of  homeopathic  veterinary 
medicinal  products  must  be  harmonized  to  permit  the 
circulation  throughout  the  Community  of preparations 
which are safe  and of good quality; 
Whereas,  having  regard to the  particular characteristics 
of  these  medicinal  products,  such  as  their  very  low 
content of active principles arid the difficulty of applying 
to them  the  conventional statistical  methods  relating to 
clinical  trials,  it  is  appropriate  to  provide  a  simplified 
registration  system  for  those  traditional  homeopathic 
veterinary medicinal  products which  are  placed  on the 
market  without  specific  therapeutic  indications  in  a 
preparation which does not present a risk for the animal 
or the consumer of animal products; 
Whereas, however,  the  usual  rules  governing  the  auth-
orization to market veterinary medicinal products should 
be  applied  to  a  homeopathic  veterinary  medicinal 
product  marketed  with  therapeutic  indications  or in  a 
form  which  may present risks  which  must be  balanced 
against  the  desired  therapeutic  effect;  whereas  those 
Member  States  which  have  a  homeopathic  tradition 
should be able io apply particular rules for the evaluation 
of tests  and  trials  intended  to  establish  the  safety and 
efficacy of these veterinary medicinal products provided 
that they notify them  to the Commission, 
HAS  ADOPTED THIS DIRECTNE: 
CHAPTER I 
Scope 
Article 1 
For  the  purposes  of  this  Directive  'homeopathic 
veterinary medicinal product' shall  mean any veterinary 
medicinal product prepared in accordance with a homeo-
pathic  manufacturing  procedure  described  by  the 
European Pharmacopoeia or, in the absence thereof, by 
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Homeopathic preparations are produced from  products, 
substances or compositions called homeopathic stocks by 
successive  dilutions. 
Article 2 
1.  The  provlSlons  of  this  Directive  shall  apply  to 
homeopathic  veterinary  medicinal  products  to  the 
exclusion  of  products  prepared  by  a  pharmacist  or  a 
veterinarian  in  accordance  with  a  magistral  or  an 
officinal  formula  and  intended  for  administration  to  a 
single. animal or a small  number of animals. 
2.  The medicinal products referred to in  paragraph 1 
must  be  identified  by  the  inclusion  on  their  labels  in 
clearly legible form of the words 'homeopathic medicinal 
products,  for animal treatment only'. 
3.  . This  Directive  shall  not  apply  to  immunological 
homeopathic  veterinary  medicinal  products  which  shall 
be  authorized by Member States in  accordance with the 
proyisions  of the Council r>irective  extending the  scope 
of Directive  81/851/EEC on the  approximation  of the 
laws  of  the  Member  States  relating  to  veterinary 
medicinal  products  and  laying  down  additional 
provieyions  for  immunological  veterinary  medicinal 
products. 
CHAPTER II 
Manufacture,  control and  inspection 
Article 3 
The provisions  of Chapter V  of Directive  81/851/EEC 
shall  apply  to  the  manufacture,  conttol,  import  and 
export of homeopathic veterinary medicinal products. 
Article 4 
The measures of supervision and the sanctions provided 
for in  Chapter VI of Directive 81/851/EEC shall  apply 
to homeopathic veterinary medicinal products. 
However,  the  proof of therapeutic effect  mentioned  in 
Article  37  (1)  (b)  of the  same  Directive  shall  not  be 
required  for homeopathic veterinary medicinal  products 
registered in  accordance with Article 7 of this  Directive. 
Article 5 
The Member States shall communicate to each other all 
the  information  necessary  to  guarantee  the  quality  and 
safety  of  homeopathic  veterinary  medicinal  products 
manufactured and marketed within the Community, and 
in  particular  the  information  mentioned  in  Articles  39 
and 42  of Directive 81/851/EEC. 
CHAPTER Ill 
Placing  on the  market 
Article 6 
1.  Member  States  shall  ensure  that  homeopathic 
veterinary  medicinal  products  manufactured  and 
marketed within the Commun,ity are registered or auth-
orized in accordance with the proN'isions  of Articles 7, 8 
and  9.  Each Member State  shall  take  registrations  and 
authorizations  previously  granted  by  another  Member 
State into due consideration. 
2.  A Member State may refrain from  establishing any 
system  of registration or authorization for homeopathic 
veterinary medicinal products. A Member State applying 
this provision shall inform the Commission thereof. The 
Member  State  shall  allow  the  use  in  its  territory  of 
homeopathic veterinary medicinal products registered or 
authorized by other Member States in  accordance with 
Articles  7,  8 and 9. 
Article  7 
1.  Homeopathic veterinary medicinal products shall be 
subject  to  a  simplified  registration  procedure  if  they 
satisfy all  of the following  conditions: 
- they are administered orally or externally, 
- they  are  marketed  without  any  specific  therapeutic 
indication, whether on the labelling of the medicinal 
product  or  in  any  accompanying  product  ipfor-
mation, 
there  is  a  sufficient  degree  of dilution  to guarantee 
the  safety  Of  the  preparation. and,  in  the  case  of 
homeopathic veterinary  medicinal  products intended 
for  administration  to  food-producing  animals,  to 
guarantee the  absence  of harmful  residues  in  fQod-
stuffs produced from these animals; in particular, the 
preparation  shall  contain  less  than  one  part  per 
million of any active principle which is  subject to the 
requirement of a veterinary prescription. 
2.  In  addition  to  the  clear  mention  of  the  words 
'homeopathic  medicinal  product,  fqr  animal  treatment 
only',  the  labelling  and  packaging  of the  homeopathic 
veterinary medicinal products referred to in  paragraph 1 
shall  consist of the following  information and  no other 
information: 
- the  scientific  name  of  the  stock  followed  by  the 
degree  of dilution,  using  the  symbols  used  m  the 
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- name  and  address  of  the  person  responsible  for 
marketing, and of the manufacturer, 
- method of administration, 
- expiry date, in plain language, 
- special storage precautions, if any, 
- manufacturer's batch number, 
- registration number, 
- in the case of products intended for administration to 
food-producing  animals,  a  statement that there  is  a 
nil withdrawal period. 
3.  The criteria and rules of procedure provided for in 
Articles  8 to 15  of Directive 81/851/EEC shall apply to 
the  simplified  registration  procedure  for  homeopathic 
veterinary medicinal products, with .the  exception of the 
proof of therapeutic effect. 
Article 8 
An application for a simplified registration submitted by 
the person responsible for marketing may cover a series 
of  preparations  derived  from  the  same  homeopathic 
stock.  The following  documents  shall  be  included with 
the application in order to demonstrate, in particular, the 
pharmaceutical  quality  and  the  batch-to-batch 
consistency of the products concerned: 
- scientific  name  of the  homeopathic  stock,  together 
with  a  mention  of  the  various  routes  of  adminis-
tration,  pharmaceutical  forms  and  dilutions  to  be 
registered, 
dossier  describing  how  the  stock  is  obtained  and 
controlled, and justifying its  homeopathic nature, on 
the basis of an adequate homeopathic bibliography, 
manufacturing  and  control  file  for  each  pharma-
ceutical  form  and  a  description  of  the  method  of 
dilution, 
- manufacturing  authorization  for  the  preparations 
concerned, 
- copies of any registrations or authorizations obtained 
for the same preparations in other Member States, 
- one . or  more  specimens  or  mock-ups  of  the  sales 
presentation of the preparations to be registered. 
Article 9 
Homeopathic veterinary  medicinal  products  other than 
those  referred  to  in  Article  7  shall  be  authorized  and 
labelled  in  accordance with  the provisions  of Articles  5 
to  15  of Directive 81/851/EEC, including the provisions 
concerning  proof  of  therapeutic  effect,  and  shall  be 
labelled in  accordance with the provisions of Articles 43 
to 50  of Directive 81/851/EEC. 
CHAPTER N 
Fmal  provisions 
Article 10 
1.  Member States shall take the measures necessary to 
comply with this  Directive by 31  December 1992. They 
shall  inform the Commission thereof forthwith. 
The  proviSions  adopted  pursuant  to  the  first 
subparagraph  shall  make  express  reference  to  this 
'Directive. 
2.  Applications for registration or for marketing auth-
orization for products covered by this  Directive lodged 
after the date set out in  paragraph  1 shall  comply with 
the provisions of this  Directive. 
Article  11 
This Directive is  addressed to the Member States. - 31  -
IMPACT  ON  COMPETITIVENESS  AND  EMPLOYMENT 
1.  What  Is  the main  reason  for  Introducing  the measure? 
White  Paper  on  completing  the  Internal  market;  Improvement  of 
protection of  public health;  Instructions  from  the  Councl I  to  Include 
in  Community  legislation all  Industrially produced  medicinal  products. 
2.  Features of  the  businesses concerned 
The  market  for  homeopathic  medicines  Is  relatively restricted  (2%  of 
the market  for  pharmaceuticals).  Industrial  preparation of  homeopathic 
medicines  Is carried out  by  about  15  Community  companies  which  are 
disadvantaged  by  present  legislation and  the  lack  of  legal  certainty 
for  their activities  In  some  Member  States where  homeopathy  Is  not 
recognized.  Small  manufacturing or  dl Iutton  runs  produced  by  local 
homeopathic,  dispensing  pharmacies  are  not  affected by  the proposals. 
According  to the  Information available  to  the Commission,  the 
Industrial-scale firms  are  located particularly  In  certain areas: 
France,  Germany,  United  Kingdom;  however,  their  products are already 
being  sold  throughout  the Community. 
3.  What  direct obligations does  this measure  Impose  on  businesses? 
The  measures  Introduced all  seem  necessary  to protect  the  consumer  and 
should  therefore already be  standard practice  for  a  bona  fide  producer; 
In  particular: - 32  -
-good pharmaceutical  manufacturing  practice, 
-a quai If led  person  to check  and  certify each  production  batch, 
-submission of  documentation,  especially  a  blbl iography,  to guarantee 
the  quality and  safety of  the  homeopathic.  medicines  so produced. 
Firms  must  also agree  to try  to standardize  the  qual tty of  raw 
materials and  production  processes,  as  has already  been  achieved  In 
some  countries  (Germany,  France)  but  which  stl II  remain  to be 
harmonized  In  the context  of  the  European  Pharmacopoeia  (Council  of 
Europe  convention). 
4.  What  obi igations are  local  authorities  likely  to  Impose  on  businesses? 
National-level  Inspection of  premises  and  manufacturing conditions, 
where  this  Is  not  already  Instituted by  the  national  authorities. 
5.  Do  any  special  measures  apply  In  respect  of  SMEs? 
No,  since products manufactured  by  local  pharmacies on  a  small  scale 
(magistral  and  officinal  preparations)  are not  covered  by  the  proposed 
measures. 
6.  What  Is  the  likely effect on: 
(a)  business competitiveness? 
A greater  degree of  harmonization  In  the  production of 
homeopathic  medicines  and  the authorization of  them  could 
Improve  the competitiveness of  both  manufacturers geared  to 
Intra-Community  trade and  producers with  an  Interest  In  exporting 
outside  the Community. 
(b)  employment? 
No  significant effect  Is  foreseen. - 33  -
7.  Have  both  sides of  Industry  been  consulted? 
Apart  from  the  European  federations  representing manufacturers of 
homeopathic  medicinal  products,  there  has  been  consultation of 
associations  representing  homeopathic  pharmacists  and  practitioners. 
The  result  has  been  general  agreement  on  the  principles behind  the 
measures  proposed. I 
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